DIVESTITURES	9 Months Ended
Sep. 30, 2026
Discontinued Operations and Disposal Groups [Abstract]
DIVESTITURES	DIVESTITURES Discontinued Operations Sale of Bile Acid Product Portfolio In August 2023, the Company closed the sale of its bile acid business to Mirum pursuant to the terms of an asset purchase agreement dated July 16, 2023 (the "Purchase Agreement"). The Company is eligible to receive up to $235.0 million upon the achievement of certain milestones based on specified amounts of annual net sales (tiered from $125.0 million to $500.0 million) of Chenodal and Cholbam (also known as Kolbam, and together with Chenodal, the "Products"). The Company will recognize the contingent consideration receivable in earnings when the target annual sales for the milestones are met and the contingency is resolved. Mirum achieved the first such milestone based on its annual net sales in 2025, and Travere recognized $25.0 million for the year ended December 31, 2025 in discontinued operations. The $25.0 million is included in accounts receivable as of December 31, 2025 and payment was received in April 2026. Mirum achieved an additional milestone based on its annual net sales in 2026, and Travere recognized $10.0 million in milestone revenue for the three and nine months ended September 30, 2026 in discontinued operations. The $10.0 million is included in accounts receivable as of September 30, 2026. Income from discontinued operations, net of tax for the three and nine months ended September 30, 2026 was $8.7 million and $8.2 million, respectively and zero for both the three and nine months ended September 30, 2025. The Company corrected an immaterial presentation error from a prior period in its consolidated statement of cash flows for the nine months ended September 30, 2026. The previously presented cash flows for the six months ended June 30, 2026 incorrectly included cash flows of $24.5 million in cash provided by operating activities - continuing operations and should have been reflected in cash provided by operating activities - discontinued operations. The correction would have resulted in cash used in operating activities - continuing operations of $6.8 million and cash provided by operating activities - discontinued operations of $24.5 million for the six months ended June 30, 2026. The correction does not affect total cash flows from operating activities or the reported net change in cash and cash equivalents. The Company evaluated the materiality of the error in its statement of cash flows, including its effect on the previously issued consolidated financial statements and the financial statements taken as a whole, and concluded that the error was not material to the previously issued consolidated financial statements. Accordingly, the Company has corrected the presentation of the cash flows during the nine months ended September 30, 2026.

DIVESTITURES

9 Months Ended

Sep. 30, 2026

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

Sale of Bile Acid Product Portfolio

In August 2023, the Company closed the sale of its bile acid business to Mirum pursuant to the terms of an asset purchase agreement dated July 16, 2023 (the "Purchase Agreement"). The Company is eligible to receive up to $235.0 million upon the achievement of certain milestones based on specified amounts of annual net sales (tiered from $125.0 million to $500.0 million) of Chenodal and Cholbam (also known as Kolbam, and together with Chenodal, the "Products"). The Company will recognize the contingent consideration receivable in earnings when the target annual sales for the milestones are met and the contingency is resolved. Mirum achieved the first such milestone based on its annual net sales in 2025, and Travere recognized $25.0 million for the year ended December 31, 2025 in discontinued operations. The $25.0 million is included in accounts receivable as of December 31, 2025 and payment was received in April 2026. Mirum achieved an additional milestone based on its annual net sales in 2026, and Travere recognized $10.0 million in milestone revenue for the three and nine months ended September 30, 2026 in discontinued operations. The $10.0 million is included in accounts receivable as of September 30, 2026. Income from discontinued operations, net of tax for the three and nine months ended September 30, 2026 was $8.7 million and $8.2 million, respectively and zero for both the three and nine months ended September 30, 2025.

The Company corrected an immaterial presentation error from a prior period in its consolidated statement of cash flows for the nine months ended September 30, 2026. The previously presented cash flows for the six months ended June 30, 2026 incorrectly included cash flows of $24.5 million in cash provided by operating activities - continuing operations and should have been reflected in cash provided by operating activities - discontinued operations. The correction would have resulted in cash used in operating activities - continuing operations of $6.8 million and cash provided by operating activities - discontinued operations of $24.5 million for the six months ended June 30, 2026. The correction does not affect total cash flows from operating activities or the reported net change in cash and cash equivalents. The Company evaluated the materiality of the error in its statement of cash flows, including its effect on the previously issued consolidated financial statements and the financial statements taken as a whole, and concluded that the error was not material to the previously issued consolidated financial statements. Accordingly, the Company has corrected the presentation of the cash flows during the nine months ended September 30, 2026.